Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariano Esteban

Showing results (31-40 of 256) with videos related to

Pageof 26
Sort By:
Virus Research|October 11, 2005
Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gammaFernando Abaitua, Juan Ramón Rodríguez, Ana Garzón, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 15, 2024
Current situation in the development of a preventive HIV vaccineJosé Alcamí, Joan Joseph Munné, María Ángeles Muñoz-Fernández, et al.
Plos Pathogens|July 8, 2008
Vaccinia virus E3 protein prevents the antiviral action of ISG15Susana Guerra, Ana Cáceres, Klaus-Peter Knobeloch, et al.
Cellular Microbiology|August 22, 2007
Membrane cell fusion activity of the vaccinia virus A17-A27 protein complexGrazyna Kochan, David Escors, José Manuel González, et al.
Vaccine|May 19, 2009
Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigensCarmen E Gómez, José L Nájera, Raquel Sánchez, et al.
Journal of Virology|April 21, 2017
Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune ResponseMauro Di Pilato, Ernesto Mejías-Pérez, Carlos Oscar S Sorzano, et al.
Journal of Virology|January 7, 2014
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigensJuan García-Arriaza, Carmen E Gómez, Carlos Óscar S Sorzano, et al.
Plos One|February 12, 2011
Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergenceElena Domingo-Gil, René Toribio, José Luis Nájera, et al.
Current Gene Therapy|April 2, 2011
MVA and NYVAC as vaccines against emergent infectious diseases and cancerCarmen E Gómez, José L Nájera, Magdalena Krupa, et al.
Anales De Pediatria|February 17, 2024
Thirty-day readmissions in children with complex chronic conditionsDaiana Basso, Carolina Bermúdez, Vanessa Carpio, et al.
Pageof 26

Showing results (31-40 of 256) with videos related to

Sort By:
Pageof 26
Virus Research|October 11, 2005
Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gammaFernando Abaitua, Juan Ramón Rodríguez, Ana Garzón, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 15, 2024
Current situation in the development of a preventive HIV vaccineJosé Alcamí, Joan Joseph Munné, María Ángeles Muñoz-Fernández, et al.
Plos Pathogens|July 8, 2008
Vaccinia virus E3 protein prevents the antiviral action of ISG15Susana Guerra, Ana Cáceres, Klaus-Peter Knobeloch, et al.
Cellular Microbiology|August 22, 2007
Membrane cell fusion activity of the vaccinia virus A17-A27 protein complexGrazyna Kochan, David Escors, José Manuel González, et al.
Vaccine|May 19, 2009
Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigensCarmen E Gómez, José L Nájera, Raquel Sánchez, et al.
Journal of Virology|April 21, 2017
Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune ResponseMauro Di Pilato, Ernesto Mejías-Pérez, Carlos Oscar S Sorzano, et al.
Journal of Virology|January 7, 2014
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigensJuan García-Arriaza, Carmen E Gómez, Carlos Óscar S Sorzano, et al.
Plos One|February 12, 2011
Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergenceElena Domingo-Gil, René Toribio, José Luis Nájera, et al.
Current Gene Therapy|April 2, 2011
MVA and NYVAC as vaccines against emergent infectious diseases and cancerCarmen E Gómez, José L Nájera, Magdalena Krupa, et al.
Anales De Pediatria|February 17, 2024
Thirty-day readmissions in children with complex chronic conditionsDaiana Basso, Carolina Bermúdez, Vanessa Carpio, et al.
Pageof 26